Filing Details

Accession Number:
0001179110-12-013911
Form Type:
4
Zero Holdings:
No
Publication Time:
2012-09-11 18:07:44
Reporting Period:
2012-09-07
Filing Date:
2012-09-11
Accepted Time:
2012-09-11 18:07:44
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1034842 Rigel Pharmaceuticals Inc RIGL Pharmaceutical Preparations (2834) 943248524
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1363984 D Ryan Maynard Rigel Pharmaceuticals, Inc.
1180 Veterans Blvd.
South San Francisco CA 94080
Evp & Cfo No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2012-09-07 34,112 $6.49 34,112 No 4 M Direct
Common Stock Disposition 2012-09-07 34,112 $10.55 0 No 4 S Direct
Common Stock Acquisiton 2012-09-10 17,586 $6.49 17,586 No 4 M Direct
Common Stock Disposition 2012-09-10 17,586 $10.52 0 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2012-09-07 34,112 $0.00 34,112 $6.49
Common Stock Stock Option (Right to Buy) Disposition 2012-09-10 17,586 $0.00 17,586 $6.49
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
114,188 2019-03-30 No 4 M Direct
96,602 2019-03-30 No 4 M Direct
Footnotes
  1. The shares vest month over one(1) year from 3/30/09.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.50 to $10.76, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or Securities and Exchange Commission, full information regarding the shares sold at each separate price within the range set forth in footnote (2) of this Form 4.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.50 to $10.57, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or Securities and Exchange Commission, full information regarding the shares sold at each separate price within the range set forth in footnote (3) of this Form 4.